- Home
- DVAX vs OMCL Comparison
DVAX vs OMCL Comparison
Compare DVAX & OMCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- OMCL
- Stock Information
- Founded
- DVAX 1996
- OMCL 1992
- Country
- DVAX United States
- OMCL United States
- Employees
- DVAX N/A
- OMCL N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- OMCL Computer Manufacturing
- Sector
- DVAX Health Care
- OMCL Technology
- Exchange
- DVAX Nasdaq
- OMCL Nasdaq
- Market Cap
- DVAX 1.3B
- OMCL 1.5B
- IPO Year
- DVAX 2004
- OMCL 2001
- Fundamental
- Price
- DVAX $9.70
- OMCL $32.32
- Analyst Decision
- DVAX Buy
- OMCL Buy
- Analyst Count
- DVAX 4
- OMCL 7
- Target Price
- DVAX $26.50
- OMCL $46.71
- AVG Volume (30 Days)
- DVAX 1.9M
- OMCL 489.5K
- Earning Date
- DVAX 11-06-2025
- OMCL 10-29-2025
- Dividend Yield
- DVAX N/A
- OMCL N/A
- EPS Growth
- DVAX N/A
- OMCL N/A
- EPS
- DVAX N/A
- OMCL 0.49
- Revenue
- DVAX $316,268,000.00
- OMCL $1,149,529,000.00
- Revenue This Year
- DVAX $23.23
- OMCL $5.37
- Revenue Next Year
- DVAX $16.57
- OMCL $3.67
- P/E Ratio
- DVAX N/A
- OMCL $65.45
- Revenue Growth
- DVAX 26.66
- OMCL 6.39
- 52 Week Low
- DVAX $9.20
- OMCL $22.66
- 52 Week High
- DVAX $14.63
- OMCL $55.75
- Technical
- Relative Strength Index (RSI)
- DVAX 41.54
- OMCL 52.19
- Support Level
- DVAX $9.20
- OMCL $31.73
- Resistance Level
- DVAX $9.94
- OMCL $33.32
- Average True Range (ATR)
- DVAX 0.30
- OMCL 0.91
- MACD
- DVAX -0.05
- OMCL -0.17
- Stochastic Oscillator
- DVAX 40.65
- OMCL 38.25
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.